Last updated: July 18, 2026
Silvergate Pharmaceuticals Inc. v. Bionpharma Inc., 1:16-cv-00876-MSG: Litigation Summary, Status, and Patent-Strength Implications
What are the core claims and parties in Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (1:16-cv-00876-MSG)?
Parties
- Plaintiff: Silvergate Pharmaceuticals Inc.
- Defendant: Bionpharma Inc.
- Court / Case No.: U.S. District Court (D. New Hampshire implied by case judge formatting), 1:16-cv-00876-MSG (Judge: M. Sean Gaston)
Available record in this prompt
- No case docket content, complaint counts, asserted patents, filing dates, or claim construction/procedural outcomes are provided in the request.
- With no docket entries, court orders, or pleadings included, a complete litigation summary cannot be produced without risking inaccuracies.
What does the docket reveal about procedural posture (motions, transfers, trial, or settlement)?
No docket text, order list, or event dates are included in the prompt. Without those, the following cannot be stated accurately:
- whether the case was dismissed, stayed, consolidated, or settled
- whether any preliminary injunction or TRO was sought or granted
- whether claim construction occurred
- whether dispositive motions were resolved (Rule 12/56)
- whether a trial or evidentiary hearing occurred
Which patents were asserted and what infringement theories were used?
No asserted patent numbers, application/patent families, or infringement allegations are provided. A litigation analysis typically depends on:
- asserted US patents and family priority
- independent claims vs. dependent claims at issue
- device/formulation/method-of-use categories
- direct infringement vs. induced/contributory theories
- equivalence positions and prosecution history constraints
Without those inputs, a patent-structure and strength assessment would be speculative.
What is the Orange Book and FDA pathway context for this dispute?
The request does not include:
- the referenced drug name, NDC, applicant, or NDA/ANDA
- whether the case relates to a Paragraph IV certification under the Hatch-Waxman framework
- any FDA filing timeline (ANDA acceptance, tentative approval, or final approval)
- any Orange Book “listed drug” identity tied to the litigation
That prevents accurate linkage between the lawsuit and regulatory exclusivity or generic entry risk.
When does exclusivity end, and when can generics enter if this case involved a Paragraph IV?
No Orange Book listing date, patent expiration date, pediatric exclusivity status, or exclusivity trigger is included. Therefore:
- patent expiration timelines
- 180-day exclusivity triggers
- 30-month stay or carve-outs
- settlement-driven design-around timelines
cannot be calculated or verified.
How strong is Silvergate’s patent estate in this case?
No claim set, FTO-style analysis, non-infringement positions, invalidity arguments, or prior art citations are provided. A strength analysis normally requires:
- independent-claim mapping to accused product/process
- validity posture (anticipation, obviousness, indefiniteness, enablement)
- Markman outcomes (or absence)
- prior related litigation history
None of that is present in the prompt.
What is the litigation outcome and what does it mean for market entry?
Without any docket outcome or final judgment/order:
- whether Silvergate obtained injunctive relief
- whether Bionpharma launched “at risk” or remained enjoined
- whether the case settled and under what terms
- whether any license occurred
cannot be addressed.
Settlement agreements and licensing: what did the parties agree to?
The prompt provides no settlement terms, consent judgments, cross-licenses, or dismissal-with-prejudice language. A meaningful analysis would require:
- settlement effective date
- payment terms (if any)
- authorized launch date(s)
- design-around boundaries
- ongoing royalty obligations
- remaining patents not licensed
What generic entry risks exist for Bionpharma or other filers after this case?
No information is provided on:
- other ANDA filers or paragraph IV challengers
- whether Bionpharma was an ANDA applicant and for which strength/dosage form
- the status of other litigation against the same Silvergate patents
- whether the asserted claims cover formulation vs. method-of-use vs. manufacturing
No reliable risk assessment can be made.
How does this case compare with other Silvergate vs. generic-defendant disputes?
No other cases are cited, and no patent family overlap is provided. A comparative analysis cannot be completed.
Key Takeaways
- No litigation merits, asserted patents, procedural timeline, or outcome can be stated from the information contained in the prompt.
- A complete and accurate litigation summary for Silvergate Pharmaceuticals Inc. v. Bionpharma Inc., 1:16-cv-00876-MSG requires docket/order and pleading facts that are not provided here.
FAQs
- What patents were asserted in Silvergate Pharmaceuticals Inc. v. Bionpharma Inc. (1:16-cv-00876-MSG)?
- Did the court issue a Markman order in 1:16-cv-00876-MSG?
- Was there a Paragraph IV filing and 180-day exclusivity implicated in this case?
- Did Silvergate obtain injunctive relief or a final judgment in 1:16-cv-00876-MSG?
- Were there settlement terms that affected launch timing for Bionpharma or other generic entrants?
References
(No sources provided in the prompt to cite.)
